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Abstract With contemporary therapeutic strategies in multi-
ple myeloma, heretofore unseen depth and rate of responses
are being achieved. These strategies have paralleled improve-
ments in outcome of multiple myeloma patients. The integra-
tion of the next generation of proteasome inhibitors and anti-
body therapeutics promise continued improvements in thera-
py with the expectation of consistent depth of response not
quantifiable by current clinical methods. As such, there is a
growing need to develop adequate tools to evaluate deeper
disease response after therapy and to refine the response
criteria including the minimal residual disease. Several emerg-
ing techniques are being evaluated for these purposes includ-
ing multi-parameter flow cytometry, allele-specific oligonu-
cleotide polymerase chain reaction, next-generation sequenc-
ing, and imaging modalities. In this review, we highlight the
recent developments and evaluate advantages and limitations
of the current technologies to assess minimal residual disease.
We also discuss future applications of these methodologies in
potentially guiding multiple myeloma treatment decisions.
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Introduction
Multiple myeloma is a heterogeneous plasma cell neoplasm
which remains all but incurable despite recent significant ad-
vances in its treatment with various proteasome inhibitors [1],
immunomodulatory agents, monoclonal antibodies [2, 3], his-
tone deacetylase inhibitors [4, 5], and widespread use of high-
dose melphalan followed by autologous hematopoietic cell
transplantation (HCT) and maintenance therapy [6–11].
Multiple myeloma is a unique neoplasm where disease activ-
ity and burden can be quantified by a number of different
modalities including biochemical analysis (protein or light
chain quantification as surrogate markers), bone marrow plas-
ma cell involvement, and functional imaging such as positron
emission tomography (PET) [12]. Whole body magnetic res-
onance imaging (MRI) has also been evaluated for assessing
response with negativity after autologous HCT associated
with improved prognosis [13]. A number of studies have in-
dicated that deeper responses and achievement of complete
response (CR) can serve as a treatment benchmark for longer
disease control and survival [14–16].
With increasing number of available therapeutic options in
myeloma, probability of achieving CR and stringent CR
(sCR) is steadily improving as shown in a recent frontline
phase 1/2 study where a combination of carfilzomib,
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lenalidomide, and dexamethasone resulted in unprecedented
sCR rate of 42 % with early clinical trials suggesting even
greater depths of response in the near future [17]. However,
these excellent responses are unfortunately not always sustained
and many patients (if not all) experience disease progression or
relapse primarily due to residual myeloma reservoir through
environment-mediated drug resistance and/or the persistence of
myeloma stem cells [18, 19]. This underscores the importance of
defining further and deeper response beyond sCR.
We have reached another important era in multiple myelo-
ma with expanding treatment options. To this end, our ability
to quantify low-level disease burden and our response criteria
must keep pace. Several sensitive technologies to assess min-
imal residual disease (MRD) in myeloma have been devel-
oped and are clinically available although no consensus exists
on how andwhen to use these newer methods for the detection
and monitoring of MRD. In this review, we focus on technol-
ogies such as multi-parameter flow cytometry (FCM), poly-
merase chain reaction (PCR), and next-generation sequencing
(NGS) to assess MRD burden in the context of multiple my-
eloma treatment.
Refinement of CR Criteria by International
Myeloma Working Group
With the growing knowledge on MRD assessment, the up-
dated International Myeloma Working Group (IMWG) re-
sponse criteria in 2011 incorporated some new designations
to traditional CR definitions [16]. BImmunophenotypic CR^ is
defined as absence of phenotypically aberrant clonal plasma
cells in bone marrow with a minimum total of one million
bone marrow cells analyzed by multi-parameter FCM (with
≥4 colors). Additionally, Bmolecular CR^ is now defined as
confirmation of CR plus negative allele-specific oligonucleo-
tide PCR (sensitivity 10−5) [16]. This represents a step forward
in adapting new and emerging technologies to official re-
sponse criteria. Whether these endpoints will be proven to
be the clinical relevant endpoints [20] remains to be seen,
and the IMWG response criteria are expected to evolve even
more in the near future. In the next sections, wewill review the
technologies being assessed for MRD quantification at this
time as well as potential future options.
Multi-Parameter Flow Cytometry
Principles of FCM in Myeloma
Multi-parameter FCM is probably the most commonly avail-
able technique that allows quantifications of MRD assess-
ment. The technique employs different cocktails of antibodies
targeting unique plasma cell surface protein expression
enabling differentiation of normal versus abnormal (or aber-
rant) plasma cells in the bone marrow aspirate samples.
Almost a decade ago, the European Myeloma Network
(EMN) convened FCM workshops for myeloma and reported
a list of most useful antigens for the detection of aberrant
plasma cells [21]. In addition to CD38, CD138, and CD45,
markers such as CD19 (negative) and CD56 (positive) were
considered essential for detection of abnormal plasma cells.
The panel recommended additional antibodies to be included
such as CD117, CD20, CD28, and CD27 for prognostication.
Although data were limited, CD81 and CD200 were also sug-
gested to be also included [21].
Figure 1 shows some representa t ive aber rant
immunophenotype of neoplastic plasma cells. The develop-
ment and use of therapeutic anti-CD38 antibodies, such as
daratumumab [22], which could reduce the expression of
CD38 on the plasma cells, has also made it necessary to search
for alternative markers for the identification of normal or neo-
plastic plasma cells. CD269, CD319, CD229, and CD54 have
been found to be valuable for this purpose. CD269 and
CD319were found to identify plasma cells under substantially
more diverse conditions than CD138, including within de-
layed samples [23].
Multi-parameter FCM is generally applicable to majority
of myeloma patients with a sensitivity ranging from 10−4 to
10−5 (1 in 10,000 to 100,000 cells) [21, 24–26]. However,
expertise is required to construct adequate antibody panel for
multi-parameter FCM forMRD assessment in myeloma. Each
center and FCM laboratory may choose desired antibody
cocktails and fluorochromes of their choices and the panels
would need to be validated prior to clinical use. Consistent
application of FCM technique and interpretation of FCM anal-
ysis by experienced pathologists are also essential for reliable
reporting of MRD in myeloma. Many colors as much as 10
(i.e., 10-color flow panel) are available in recent flow
cytometer expanding the ability to simultaneously target mul-
tiple antibodies for FCM analysis.
Using the principles outlined by the EMN [21], Medical
Research Council (MRC) Myeloma IX Study performed the
multi-parameter FCM in a single laboratory (in Leeds, UK)
where a six-color panel of CD138, CD45, CD38, CD19,
CD56, and CD27 was used [27••]. This study demonstrated
the predictive ability of multi-parameter FCM performed at
100 days after autologous HCT [27••]. In an effort to stan-
dardize the flow panel, the EuroFlow (a division of European
Scientific foundation for Laboratory HematoOncology, www.
euroflow.org) reported a validated eight-color flow panel for
myeloma FCM [28]. They proposed two tubes to be used for
the eight-color panel FCM: tube 1 (CD45/CD138/CD38/
CD56/beta-2 microglobulin/CD19/cytoplasmic Ig kappa/
cytoplasmic Ig lambda) and tube 2 (CD45/CD138/CD38/
CD28/CD27/CD19/CD117) [28]. These panels are designed
to use four backbone markers (CD38/CD138/CD45/CD19)
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and eight additional markers for further identification,
enumeration, and characterization of neoplastic plasma
cells.
Monitoring of MRD with FCM After Treatment
At least two large studies evaluated the predictability of multi-
parameter FCM on multiple myeloma treatment (Table 1).
Paiva et al. assessed MRD status at day +100 by multi-
parameter FCM in 295 newly diagnosed multiple myeloma
patients treated with induction followed by autologous
HCT in the GEM2000 protocol [29]. Compared to
MRD-positive patients at day +100, those with MRD-
negative status had longer progression-free survival
(PFS; median 71 vs. 37 months, P< 0.001) and overall
survival (OS; median not reached vs. 89 months,
P = 0.002: Table 1) [29]. In multivariate analyses,
MRD status by multi-parameter FCM at day +100 after
autologous HCT was the most important independent
prognos t i c fac to r fo r bo th PFS (hazard ra t io
(HR) = 3.64, P= 0.002) and OS (HR=2.02, P= 0.02).
Rawstron et al. evaluated the role of multi-parameter
FCM in assessing MRD after induction therapy
(n = 378) and at day +100 after autologous HCT
(n= 397) in MRC Myeloma IX Study [27••]. MRD sta-
tus at day +100 after autologous HCT was highly pre-
dictive of the survival: median PFS 28.6 vs. 15.5 months
(P < 0.001) and median OS 80.6 vs. 59 months
(P= 0.0183) for MRD-negative and MRD-positive pa-
tients, respectively (Table 1) [27••]. In both studies for
patients achieving CR, MRD-negative status was associ-
ated with better PFS but not with OS in MRC Myeloma
IX Study [27••, 29]. In the MRC Myeloma XI trial, the
best outcome was noted in patients with favorable cy-
togenetics and MRD-negative status with the worse out-
come seen in patient with adverse cytogenetics and
MRD-positive status for both PFS and OS (P< 0.001)
[27••]. Although some studies appear to show prognos-
tic values of MRD status for survivals in high-risk myeloma
population, it is important to note that further improvement in
treatment options and/or strategies is clearly needed for high-
risk disease due to overall inferior prognosis.
Fig. 1 Characterization of neoplastic plasma cells by multi-parameter
flow cytometry. The plasma cells are identified by gating on CD38+
(strong) and CD138+ cells (a). The neoplastic plasma cells are detected
by light chain restriction (b), aberrant expression of CD56 (c), or CD117
(d), increased expression CD200 (d, f) or CD28 (e), and decreased
expression of CD27 (e) or CD81 (f). Note: the demonstration shown is
compiled from different patients
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Limitations of Multi-Parameter FCM
Although multi-parameter FCM is likely the most widely
available technique with excellent sensitivity, a number of
potential issues may limit its application. A major limitation
of FCM is the requirement for quality bone marrow sampling.
Other institutional level limitations may include the lack of
standardization of FCM protocols and variability in sensitivi-
ty, panels, and performance among the pathology and/or FCM
laboratories. Roschewski et al. surveyed 27 academic institu-
tions in the USA and reported wide variations inMRD assess-
ment practices in 2014 [30]. Among the 11 institutions that do
perform FCM, there was a considerable heterogeneity in its
methodology including antibody panels and sensitivity of
multi-parameter FCM [30]. There is an ongoing need to have
an accepted, uniform, and standardized FCMmethodology for
MRD analysis in myeloma which would help improve overall
quality of care provided to myeloma patients and facilitate the
advancement of MRD assessment technology.
In addition, first-generation FCM techniques lacked the
sensitivity of allele-specific oligonucleotide (ASO) PCR and
NGS. These initial FCM assays allowed reproducible detec-
tion limits of 10−4 and more recently to 10−5. However, recent
reports from the EuroFlow Consortium and International
Myeloma Foundation indicate that evenmore sensitive assess-
ment is feasible with novel design and the utilization of larger
number of cells (e.g., next-generation FCM) [31]. Further,
although in a small subset analysis, the authors demonstrated
that next-generation FCM outperformed NGS [31]. These
suggest that the sensitivity of multi-parameter FCM may be
able to approach that of the molecular techniques.
Polymerase Chain Reaction (Using Allele-Specific
Oligonucleotide)
Principles of ASO-PCR in Myeloma
ASO-PCR was developed as a means to detect the unique
(clonal) rearrangements in the V(D)J-junctional regions of
the germline Ig genes in lymphoid cells. As such, these re-
gions provide veritable fingerprints for individual patients
[32•]. For nearly two decades, the concept of ASO-PCR has
evolved from nested primers to real-time quantitative PCR to
quantitate the disease burden (MRD status) relative to a diag-
nostic sampling in a number of B cell malignancies including
myeloma [33, 34]. As a mature B cell malignancy, multiple
myeloma has also undergone somatic hypermutation which
further alter the V(D)J regions. These highly mutated regions
have mitigated the widespread utilization of ASO-PCR being
applicable to a limited number of myeloma patients [32•].
However, the use of parallel quantification of IgH (heavy
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rearrangements has been utilized to decrease the false discov-
ery rates [35, 36].
PCR for ASO has been thought to be the most sensitive
methodology for the detection of abnormal plasma cells with
potential sensitivity limit of 10−5 to 10−6. In a small study
(n=14), patients who achieved CR after allogeneic HCTwere
assessed for ASO-PCR [37]. Seven patients (50 %) who
achieved molecular CR (negative ASO-PCR) did not relapse
after a median follow-up of 60 months [37]. In contrast, only
one out of other seven patients who never achieved molecular
CR relapsed suggesting a very high sensitivity of the assay
[37]. Martinez-Sanchez et al. utilized fluorescent-PCR to as-
sess IgH incomplete rearrangements (DHJ) and light chain
genes to overcome problems of somatic mutations in JH seg-
ments for MRD assessment in GEM2000 protocol [38].
Fluorescent-PCR was feasible in 91 % of patients, and the
results were overall similar to FCM. Multivariate analysis
showed fluorescent-PCR to be the only variable for prognostic
significance for PFS [38].
Monitoring of MRD with ASO-PCR After Treatment
MRD-negative status defined by ASO-PCR has been
shown to correlate with improved patient outcomes.
Although a relatively small study, Ladetto et al. evalu-
ated 39 patients receiving bortezomib, thalidomide, and
dexamethasone consolidation after autologous HCT with
real-time quantitative PCR [39]. Molecular remission
defined by real-time quantitative PCR improved from
3 % after autologous HCT to 18 % after bortezomib,
thalidomide, and dexamethasone consolidation [39]. The
sensitivity of this method was reported at 5 × 10−6 and,
importantly, no patients who achieved molecular remis-
sion had progressed after a median follow-up of
42 months. This study documents the possibility of
achieving molecular response with consolidation therapy
after autologous HCT without performing allogeneic
HCT [39].
Puig et al. compared real-time quantitative ASO-PCR and
multi-parameter FCM in three consecutive Spanish myeloma
trials enrolling 170 patients [40••]. The applicability of PCR
technique was limited to 42% of cases due to lack of clonality
detection, unsuccessful sequencing, and suboptimal ASO
performance [40••]. When MRD status was assessed in
103 patients, there was a significant correlation in MRD
quantification for both techniques and patients with
<10−4 residual myeloma cells had longer PFS compared
to the other (median PFS not reached vs. 31 months,
P= 0.002) [40••]. The study underscores the strength of
real-time quantitative ASO-PCR for higher sensitivity;
however, it also uncovered its limited applicability and
multi-parameter FCM deems to be a more practical
method for MRD assessment.
Limitations of ASO-PCR
ASO-PCR represents a novel technology with high sensitivity
for assessing the presence of MRD in myeloma. However,
ASO-PCR does carry potential limitations. The widespread
applicability ASO-PCR has been attenuated by cost, extended
turnaround time, and a need for a design of a patient-specific
ASO primer (requiring a diagnostic sample). The applicability
of ASO-PCR in myeloma is made more difficult as a conse-
quence of somatic hypermutation which further alter the
V(D)J regions. These highly mutated regions alter sequence
and thus increase the difficulty of designing primers for quan-
tification making ASO-PCR applicable to only 60–70 % of
myeloma patients [32•, 40••]. However, the use of alternate
PCR techniques continues to improve the applicability [35,
36]. Any subsequent gene mutations (i.e., tumor evolution)
would invalidate the utility of Ig derived from an original
sample. Taken together, these data demonstrate that although
both the sensitivity and specificity may be quite high when
patient-specific ASO-PCR is performed, difficulty in
generalizability of this technique hampers its dissemina-
tion in clinical practice [41•].
Next-Generation Sequencing
Principles of NGS in Myeloma
With rapid technological advances, NGS has been applied to
many lymphoid malignancies as a deep sequencing method
for monitoring of disease activity and assessment of MRD
[41•–45]. NGS employs multiplex sequencing of immuno-
globulin heavy chain (IgH) for B lymphocytes and plasma
cells. Typically, diagnostic sample from the initial biopsy (ei-
ther bone marrow or plasmacytoma) would be required to
identify unique IgH rearrangements present in the original
clone. It is possible that several clones may be discovered
from the diagnostic sample. Using the information obtained
from the diagnostic sample, subsequent samples both in bone
marrow and peripheral blood could be assessed to identify
amplified IgHs. The sensitivity of NGS using IgH sequences
may approach 10−6 or better. Once clonal patterns of individ-
ual malignancy are established, these can be monitored over
the course of therapy. The use of NGS in multiple myeloma
provides an exciting avenue to utilize a highly sensitive and
specific platform that may overcome some of the limitations
of ASO-PCR techniques.
Monitoring of MRD with NGS After Treatment
Martinez-Lopez et al. evaluated the prognostic value of NGS
method for MRD assessment using a sequencing-based plat-
form in 133 multiple myeloma bone marrow samples from
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patients treated under various GEM protocols and achieved at
least very good partial response (VGPR) after frontline thera-
py [46••]. High-throughput sequencing (HTS) was performed
by amplifying genomic DNA using locus-specific primer sets
for the IgH locus complete (IgH-VDJH), IgH incomplete
(IgH-DJH), and immunoglobulin kappa (IGK) locus [46••].
The MRD was defined as <10−5 and the assessment by NGS
was applicable in 91 % of patients. MRD-negative status by
HTS was associated with significantly longer time to progres-
sion (TTP) (median 80 vs. 31 months, P<0.0001) and OS
(median not reached vs. 81 months, P=−.02) [46••]. Deeper
response appears to show better disease control where median
TTP was 27 vs. 48 vs. 80 months for MRD levels ≥10−3 vs.
10−3 to 10−5 vs. <10−5 (P values from 0.003 to 0.0001), re-
spectively [46••]. When compared with other MRD method-
ologies, concordance rates between NGS and multi-parameter
FCM, and NGS and ASO-PCR were 83 and 85%, respective-
ly [46••]. In patients who achieved CR, MRD-negative status
by NGS resulted in significantly longer TTP (median 131 vs.
35 months, P=0.0009). This study illustrates the powerful
potential of NGSmethod in assessingMRD and its correlation
with clinical outcomes.
Limitations of NGS
Although NGS provides what appears to be increased sensi-
tivity and applicability to myeloma patients, it too has limita-
tions. NGS can be limited in its ability to capture a clonotype
in all samples in spite of adequate samples [41•]. NGS remains
the least MRD testing modality studied and continued clinical
correlations will be required for standardization and utiliza-
tion. Lastly, NGS may be susceptible to the heterogeneity or
the evolving heterogeneity of myeloma with therapy. Over
37 % of myeloma patients will contain multiple evolved
clonotypes [45]. Further, with therapy, new immunoglobulin
clonotypes may emerge, suggesting ongoing mutational pro-
cesses that could limit the sequential testing of NGS without
clear appreciation of the clonal dynamics.
Imaging in the Assessment of MRD
One of the foreseen limitations of the MRD assessment tech-
niques outlined thus far is the dependence on bone marrow
sampling. It has long been perceived that multiple myeloma is
a patchy rather than diffusely infiltrative marrow process. As
such, the accuracy of multi-parameter FCM, ASO-PCR,
and NGS testing for MRD assessment may be attenuat-
ed by this nature of myeloma marrow infiltration pat-
tern. To address this issue in part, highly sensitive im-
aging techniques with PET/CT and MRI may represent
plausible solutions.
MRI
Historically, the assessment of multiple myeloma bone disease
was carried out via skeletal surveys which are at best only able
to capture macroscopic disease. Fortunately, contemporary
imaging techniques are able to provide a much greater sensi-
tivity. MRI represents a highly sensitive and non-invasive mo-
dality to assess intramedullary and extramedullary diseases.
Multiple myeloma lesions are typically identified as low-
signal intensity on T1-weighted imaging and high-signal in-
tensity on T2-weighted imaging. Whole body MRI have been
demonstrated to be prognostic demonstrating that an increased
number of focal lesions correlated with an increased rate of
progression from smoldering myeloma to symptomatic dis-
ease [13, 47].
Importantly, the sensitive nature of MRI also positions it as
an additional modality to assess MRD status. A number of
retrospective analyses have demonstrated that resolution of
MRI-positive lesions after autologous HCT correlates with
improved outcomes [48, 49]. These data demonstrate the high
potential of MRI as a medium for assessing MRD status.
However, MRI does have limitations. First, the whole body
MRI is not widely available. Second, MRIs are time consum-
ing and individuals with pacemakers or other non-compatible
hardware are not able to undergo imaging via this technique.
Third, although quite sensitive, MRI does not differentiate
between active and inactive lesions after therapy; as such, it
is important to ensure that 3 months have elapsed to allow for
resolution of MRI-positive lesions after the therapy [13].
PET/CT
PET/CT imaging represents an ideal combination of structural
and activity-based assessment of skeletal-related events.
Importantly, PET/CT also affords accurate characterization
of extramedullary disease, thus taking into account
intramedullary and extramedullary processes [50]. Paiva
et al. described that in a comparison of transplant-eligible
patients, PET/CTwas demonstrated to provide equivalent sen-
sitivity to whole bodyMRI; however, a greater specificity was
observed [32•]. Another study suggested that PET/CT was
superior to MRI on whole body analysis, whereas in the spine
and pelvic, MRI was comparable to PET/CT [51].
Collectively, these results highlight the potential of PET/CT
as an important structural and activity-based assessment of
MRD. Therefore, one could consider PET/CT as a routine
assessment of disease response and activity.
MRD Testing as a New Standard of Care
The growing data indicate that depth of response correlates
with improved outcomes in multiple myeloma. In a long-term
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follow-up study, Martinez-Lopez et al. demonstrated that my-
eloma patients attaining a CR after autologous HCT (before
the novel anti-myeloma agent era) have improved outcomes
relative to those not achieving those levels of response [52].
Similarly, it is presently assumed that achieving CR may be a
prerequisite for long-term survival in the era of novel agents
[53]. This experience has also been replicated in the Total
Therapy program at the University of Arkansas where in-
creased depth of response has been linked to long-term sur-
vival and possibly operational cure of myeloma [54, 55].
These data suggest that CR at minimum should be the goal
of therapy for all myeloma patients. Recent studies evaluating
the contemporary combination therapy using carfilzomib/
lenalidomide/dexamethasone induction, followed by high-
dose therapy and autologous HCT, and subsequently
carfilzomib/lenalidomide/dexamethasone consolidation have
the potential to further improve the treatment outcomes
in the frontline setting [17, 56]. Although the long-term
outcomes of the newer regimens remain to be seen,
these data illustrate the enormous potential for providing
consistently much deeper responses in newly diagnosed
multiple myeloma patients; thus, our current serological
(and nephelometric) methods of measuring myeloma re-
sponses will soon be outdated and defining new re-
sponse criteria deeper than the conventional CR will
be urgently needed.
Future Directions
Multi-parameter FCM,ASO-PCR, and NGSmay be all equal-
ly sensitive in identifying MRD; however, they are limited by
the mere fact that each is dependent on sampling of bone
marrow plasma cells. Therefore, they cannot overcome two
major limitations. First, that myeloma is notoriously a patchy
disease and bone marrow biopsies are not always representa-
tive of systemic disease burden. Second, bone marrow biop-
sies are an invasive procedure and frequent sampling remains
less than ideal in most circumstances. To this end, alternate
peripheral blood-based testing would provide important ad-
vantages over the discussed MRD testing modalities.
Assessment of peripheral blood for the monitoring of MRD
may overcome some of the logistical and sampling issues
associated with bonemarrow testing. Solid tumor studies have
demonstrated the presence of circulating tumor cells (CTC),
and circulating cell-free DNA may also facilitate the charac-
terization of the genotype of a particular tumor of interest, but
not all. The continually improving sensitivity of NGS also
highlights the potential of this kind of analysis. The feasibility
of accessing CTCs in multiple myeloma has been recently
investigated by others. Mishima et al. demonstrated that
CTCs could be identified in 80 % of patients with newly
diagnosed multiple myeloma using multi-parameter FCM.
Further, CTCs were identified in 55 % of patients with re-
lapsed myeloma [57]. Although they were able to characterize
the genotype in a number of samples, this level of detection
does not translate to MRD testing. Direct assessment of circu-
lating cell-free DNA in myeloma patients has also been ex-
amined in the context of MRD testing. In multiple myeloma
patients treated with carfilzomib/lenalidomide/dexametha-
sone, evaluation of circulating DNA has been performed.
Circulating DNA was quantifiable in all samples; however,
levels became undetectable after only four cycles of therapy
[58]. These and others suggest that emerging new assessment
tool requires further technological advances to be considered
for reliable MRD testing method.
Conclusion
The addition of the next-generation proteasome inhibitors,
histone deacetylase inhibitors, and myeloma-selective anti-
bodies to our armamentarium leads to great expectations.
Upfront combination therapies with novel combination regi-
mens without autologous HCT demonstrated near CR/CR
rates approximating 31 % after eight cycles of carfilzomib/
lenalidomide/dexamethasone [17]. Integrating autologous
HCT into carfilzomib/lenalidomide/dexamethasone treatment
resulted in near CR/CR rates of 91% [56]. Although limited in
a number of patients and follow-up, Zimmerman et al. dem-
onstrated that 15/17 evaluable patients (88%) achievedMRD-
negative status [56]. Collectively, these results highlight the
improving depth of response attainable with future manage-
ment strategies. As such, our ability to quantitate response
needs to evolve as well. Multi-parameter FCM (or next-
generation FCM), ASO-PCR, and NGS represent three highly
sensitive metrics with which to assess MRD from bone mar-
row samples. In addition, imaging with PET/CT and MRI
represents two critical techniques to assess systemic MRD
via contemporary imaging. Continued evaluation will define
which of these techniques will be adopted for assessment of
MRD (for now) alone or in combination based on generaliz-
ability, accuracy, sensitivity, as well as economic consider-
ations [59, 60]. However, achieving MRD-negative status
may not offer solutions to all of myeloma clinical challenges
and there are limitations. There remain subgroups of myeloma
patients in which MRD-negative status may not equate to
long-term survival [31, 45, 61].
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